Home
Adaptive Designs in Clinical Trials
9 April - 10 April 2018
Adaptive Designs in Clinical Trials

With recent continuous developments in biotechnology, genomics and medicine, there is a high demand for more innovative and adaptive ways to design drug development programs.With adaptive design protocols becoming ever more complex, Adaptive Designs in Clinical Trials 2018 will equip you with the latest knowledge about the changing attitudes of the regulatory bodies to adaptive designs, how technology and experimental approaches will enrich your adaptive trials and how to ameliorate risks and errors in your adaptive designs.
 

Adaptive Designs in Clinical Trials 2018 will continue the discussion on recent developments and applications of state-of-the-art adaptive design techniques in clinical research. Experienced industry experts from across the globe will discuss recent real-life applications of group sequential and adaptive enrichment designs and give presentations on confirmatory designs with treatment selection and the use of basket, umbrella and platform studies in personalised medicine. Updates on the regulatory aspects and the evaluation of the use of new digital technologies in adaptive trials will also expand your knowledge of the current outlook in adaptive designs.

FEATURED SPEAKERS

Beatrice  Panico

Beatrice Panico

Medical Assessor, MHRA
Christine Fletcher

Christine Fletcher

Executive Director Biostatistics, Amgen
Frank Fleischer

Frank Fleischer

Expert Statistician Methodology , Boehringer-Ingelheim
James Matcham

James Matcham

Head of Biometrics, Early Clinical Development, AstraZeneca
Olivier Collignon

Olivier Collignon

Biostatistician, European Medicines Agency (EMA)

Beatrice Panico

Medical Assessor, MHRA
Beatrice  Panico

Maria Beatrice Panico is currently a Medical Assessor in the Clinical Trials Unit at the Medicines and Healthcare products Regulatory Agency (MHRA).
She is a medical doctor, fully qualified in Neurology with a PhD in Neuroscience. She has extensive experience in pharmacovigilance in the pharmaceutical industry.
 

Bob Clay

Managing Director, Highbury Regulatory Science
Bob Clay

Bob Clay established a regulatory consultancy practice through Highbury Regulatory Science in 2014, supporting small/medium size companies and their investors to develop regulatory/business strategies across multiple therapeutic and geographic areas. Previously, he was VP Global Regulatory Affairs at AstraZeneca with responsible for oncology, infection and personalised healthcare. Bob is a board member of TOPRA and President during 2017; a member of the Expert Scientific Advisory Committee for Medicines for Malaria Venture (MMV). Bob has held significant leadership roles in regulatory affairs in regional and global functions at Pfizer, AstraZeneca and Kinapse.
 

Chris Harbron

Principal Statistical Scientist , Roche Products Ltd
Chris Harbron

Chris Harbron is a Principal Statistical Scientist within the Methods, Collaboration and Outreach (MCO) group of the Biostatistics function at Roche. Through a variety of roles within the pharmaceutical industry Chris has worked in all stages of the drug development pipeline from drug discovery to early and late development. He has a particular interest in the design and analysis challenges in the application and discovery of biomarkers both for Personalised HealthCare and for robust decision making. Chris has published and presented widely both within the statistical and the broader scientific literature.

Chris Jennison

Professor of Statistics, University Of Bath
Chris Jennison

Christopher Jennison is Professor of Statistics at the University of Bath, UK. His PhD research at Cornell University concerned the sequential analysis of clinical trials and he has continued to work in this area for the past 35 years. His book with Professor Bruce Turnbull, "Group Sequential Methods with Applications to Clinical Trials", is a standard text on this topic and is widely used by practising statisticians. Professor Jennison's research is informed by experience of clinical trial analysis at the Dana Farber Cancer Institute, Boston and a broad range of consultancy with Medical Research institutes and Pharmaceutical companies.

Christine Fletcher

Executive Director Biostatistics, Amgen
Christine Fletcher

Chrissie is a Regional Head in Global Biostatistical Science at Amgen and she leads a Health Technology Assessment (HTA) Biostatistics group. Chrissie has worked in the Pharmaceutical Industry for over 25 years and has experience of developing and commercialising new medicines from a variety of therapeutic areas across all phases of clinical development.

Chrissie is currently the Vice-President of the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI), and co-chair of the Clinical Development Expert Group for the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Chrissie is a Chartered Statistician and Chartered Scientist of the Royal Statistical Society (RSS). Chrissie has an MSc in Applied Statistics and a BSc (Hons) in Statistics with Management Science Techniques.
 

Corine Baayen

Senior Biostatistician, Lundbeck Pharma
Corine Baayen

Corine Baayen did her PhD in biostatistics and bioinformatics at H. Lundbeck A/S and the University of Copenhagen as part of the Marie Curie Initial Training Network MEDIASRES. She then continued to work as a biostatistician at the University Hospital of Nantes and later as a statistical consultant at Capionis in France. She is currently working as a senior statistician at Lundbeck in Denmark.

Daniela Casula

Biostatistician, GSK
Daniela Casula

Graduated in statistic and economical sciences at the University of Siena, Daniela takes a second level master in advanced biostatistic for clinical research at University of Padua.
First experience with clinical research was done in Chiron, a biotech Company, as statistical programmer starting in 2002. In 2006 the Company was acquired by Novartis and she became biostatistician assigned to influenza vaccine project, influenza vaccine that was licensed in USA in November 2009.
In 2010 she left the vaccine research for an experience in pharma and move to Chiesi Farmaceutici, in the nord of Italy, where she was appointed as senior biostatistician working mainly in CNS and Stem Cell projects. In Chiesi she had her first experience in proposing an adaptive design that was then converted in a simpler group sequential design for a phase 2b study in CNS.
In 2013 she came back to vaccine development and after a couple of years working as project statistician for rabies vaccine the Company was acquired by GSK Biologicals, becoming GSK Vaccine.
At present Daniela is the lead statistician for COPD vaccine project in GSK Vaccine.

Frank Fleischer

Expert Statistician Methodology , Boehringer-Ingelheim
Frank Fleischer

Being a trained mathematician and statistician Frank has worked for more than 10 years in the pharmaceutical industry. He is a member of the statistical methodology group at Boehringer Ingelheim. Frank is considered with methodological questions regarding adaptive designs, statistical decision making, dose finding and Bayesian data enrichment as well as with piloting these methods in clinical trials. Through this role several projects across different TAs and phases are supported. Formerly he has been a project statistician for different projects in oncology, immunology and the biosimilars.
 

Heiko Goette

Biostatistician, Merck & KGaA
Heiko Goette

Heiko has been a Biostatistician at Merck KGaA in Germany since 2009. Before this he spent 5 years working as a research assistant at the Institute of Medical Biostatistics, Epidemiology and Informatics, Johannes Gutenberg-University Mainz, Germany. He graduated with a Statistics major, University of Dortmund, Germany in 2004 and received his doctorate in 2008 from Johannes Gutenberg-University Mainz, Germany.
 

James Matcham

Head of Biometrics, Early Clinical Development, AstraZeneca
James Matcham

James Matcham is the Head of Early Clinical Development Biometrics at AstraZeneca. After completing his studies he began his career as a Research Fellow at the Applied Statistics Research Unit at the University of Kent, UK. He then completed 21 years at Amgen where he worked on the development and regulatory/reimbursement approval of many of their biotechnology products, representing the company at regulatory submissions in the US and the EU. James now leads the Biometrics team specialising in early clinical trial design, decisions and analysis at AstraZeneca. His interests include adaptive trial design, the application of Bayesian methods and quantitative decision making.

James Wason

Group Leader, MRC Biostatistics Unit
James Wason

James Wason currently holds a joint appointment between the MRC Biostatistics Unit (University of Cambridge) and Newcastle University. He leads a research group focused on development of statistical methods for more efficient trials. His research interests are adaptive designs, using biomarkers prospectively during trials and analysis of composite endpoints. As well as working on methodology, James is very interested in applying novel methods in real clinical trials. He’s currently involved in several ongoing trials using novel designs.

Loic Darchy

Head of Statistical Sciences & Modeling France, Sanofi Aventis
Loic Darchy

Michael Proschan

Mathmatical Statistician, National Institute of Allergy and Infectious Diseases
Michael Proschan

Michael Proschan has been a Mathematical Statistician in the Biostatistics Research Branch at the National Institute of Allergy and Infectious Diseases since January of 2006. Prior to coming to NIAID, he spent about 16 years at the National Heart, Lung, and Blood Institute. He co-authored the books: Statistical Monitoring of Clinical Trials: A Unified Approach, with Gordon Lan and Janet Wittes (Springer, 2006) and Essentials of Probability Theory for Statisticians, (CRC Press, 2016) with Pamela Shaw.

Dr. Proschan received his Ph.D. in Statistics from Florida State University in 1989, M.S. in Statistics from Stanford University in 1982, and B.S. in Statistics and Mathematics (double major) from Florida State University in 1980. He became a Fellow of the American Statistical Association in 2005.
 

Olivier Collignon

Biostatistician, European Medicines Agency (EMA)
Olivier Collignon

Dr Olivier Collignon works as biostatistician at the Luxembourg Institute of Health since 2011 and holds a PhD in Applied Mathematics since 2009. He is currently seconded at the European Medicines Agency in London since 2014, where he participates to the scientific evaluation of the design and results of clinical trials to obtain marketing authorization of new drugs in Europe. He is especially interested in adaptive designs, basket trials and historical controls and their applications to oncology. Dr Collignon has also been involved in the National Cancer Registry of Luxembourg with which he has led collaborations with the International Agency for Research on Cancer in Lyon.
His expertise also consists in developing variable selection methods to detect promising biomarkers and build efficient clinical prediction models.
 

Ros Walley

Statistician, UCB Pharma
Ros Walley

Ros Walley studied at Cambridge University for her degree and post-graduate qualification and has worked in Pharma for over 20 years. She has supported a wide range of preclinical, clinical and biomarker areas and she is now a member of the UCB Centre for Excellence in Statistical Innovation providing statistical consultancy across the portfolio. She has a particular focus on Bayesian statistics but more generally is interested in any statistical methodology that will facilitate clear decision-marking.

Sue Todd

Professor of Medical Statistics, University of Reading
Sue Todd

Sue is Professor of Medical Statistics within the Department of Mathematics and Statistics at the University of Reading and has over 25 years’ experience as an applied academic statistician working in the fields of clinical trials and epidemiology. Her particular research areas of interest are adaptive designs and group-sequential clinical trials. Recent research has considered methodology for novel study design and analysis in these areas, in particular seamless phase II/III clinical trials involving treatment or subpopulation selection and multiple endpoints of interest.

Tom Parke

Director of Software Solutions, Berry Consultants, LLP
Tom Parke

Tom Parke is Director of Software Solutions for Berry Consultants. Tom joined Berry Consultants in 2016 and previously worked at Tessella, a UK scientific software company where he first met Don Berry in 1998 when he managed the development and running of a software system to support Pfizer’s ASTIN Stroke trial – a ground breaking response adaptive randomization dose ranging trial designed by Don and Peter Mueller.

Following that he managed multiple projects to support different aspects of many adaptive clinical trials, mostly designed by Berry Consultants and projects to develop clinical trial simulators, first with Pfizer, then Wyeth, and finally to develop FACTS.

Tom originally graduated with joint First Class Honors in Maths and Computer Science from Bristol University, and enjoyed two decades in the software industry before stumbling upon the wonderful world of adaptive clinical trials.

 

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Opening Remarks and Introductions

Chris Jennison

Chris Jennison, Professor of Statistics, University Of Bath

clock

9:10

Group sequential tests (GSTs)

  • Motivation for sequential testing
  • Error spending tests
  • Example: A GST with a survival endpoint
  • Inference on termination of a GST
  • clock

    9:50

    Multiple testing procedures

  • Introduction to multiple testing
  • Graphical representations
  • Combining multiple testing and GSTs
  • Testing a secondary endpoint after a GST
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Adaptive clinical trial designs

  • Combination tests
  • Sample size re-estimation
  • Testing multiple hypotheses
  • Closed testing procedures
  • clock

    11:40

    Example: A survival trial with treatment selection

  • An adaptive design
  • Avoiding type I error inflation
  • Assessing the benefits of the adaptive design
  • clock

    12:20

    Closing Remarks

    clock

    12:30

    End of Workshop

    clock

    13:30

    Registration & Coffee

    clock

    14:00

    Opening Remarks and Introductions

    Tom Parke

    Tom Parke, Director of Software Solutions, Berry Consultants, LLP

    clock

    14:10

    Introduction: Basket trials, Umbrella trials and Platform trials; Whats the big attraction?

  • What are Basket, Umbrella and Platform Trials
  • If we consider the time taken, and the number of subjects tested to develop a successful treatment
  • How do these trials compare to conventional development strategies?
     
  • clock

    14:40

    Case Studies

    We will look as the similarities and differences in the designs of the platform trials for:

  • Ebola
  • Brain cancer (Glioblastoma – “GBM”).
  • Cystic Fibrosis
  • Alzheimer’s
  • clock

    15:20

    Morning Coffee

    clock

    15:50

    Statistical Issues

  •  What are the key statistical issues for a platform trial?
  • The use of adaptation
  • The use of longitudinal modelling
  • Who are the control subjects?
  • What is the required degree of type-1 error control?
  • clock

    16:30

    Political, operational and regulatory issues

  • Setting up a platform trial – where’s the money coming from?
  • Where are the treatments coming from
  • Who is more important, the subject or the provider of the novel treatment?
  • How do we consent patients
  • How do we manage: updates, limiting un-blinding, adding treatments, frequent and complex statistical analyses?
  • What do the regulators think of all this?


     

  • clock

    17:10

    Q&A and Discussion

    clock

    17:30

    Closing remarks and end of workshop

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Corine Baayen, Senior Biostatistician, Lundbeck Pharma

    clock

    9:10

    Innovations in clinical trial design: Lessons learnt from adaptive designs

    Christine Fletcher, Executive Director Biostatistics, Amgen

  • Why are adaptive designs used in clinical trials?
  • What have we learnt from adaptive designs?
  • What does the future of adaptive deigns look like?
  • Other innovations in clinical trial design
  • clock

    9:50

    MHRA: Regulatory perspective on adaptive design trials

    Beatrice Panico, Medical Assessor, MHRA

  • Points to consider for initial Clinical Trial Authorisation (CTA) applications
  • Points to consider when submitting substantial amendments
  • Safety considerations
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Real-life examples from an industry perspective: Boehringer-Ingelheim

    Frank Fleischer, Expert Statistician Methodology , Boehringer-Ingelheim

  • A confirmatory enrichment design using group-sequential and interleaving techniques
  • Comparing different adaptive enrichment designs
  • A selection design for determining the most equivalent drug formulation
  • Adaptive randomisation for cut-off determination in the early phase
  • Future areas of interest for adaptive designs in clinical development
     
  • clock

    11:40

    How does the increased use of technology and novel clinical trial design impact regulatory advice and shape development of new medicines

    Bob Clay, Managing Director, Highbury Regulatory Science

  • How does the increased use of technology in adaptive trials impact regulatory guidance?
  • What are the regulatory bodies’ attitudes to novel adaptive clinical trials?
  • What are the challenges and opportunities with novel adaptive designs
  • How will in vitro diagnostic regulations impact the application of adaptive trials?
  • What does the future for adaptive designs, in the context of other approaches to obtaining evidence on the safety, efficacy and effectiveness look like?
     
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Confirmatory Adaptive Designs involving Selection

    Sue Todd, Professor of Medical Statistics, University of Reading

  • Summary of options for trials with treatment selection
  • Consideration of trials with subpopulation selection
  • Overview of examples of trials in practice
  • clock

    14:00

    Case Study: A Phase 2/3 Adaptive Seamless Study Design in Patients with Chronic Obstructive Pulmonary Disease (COPD).

    Daniela Casula, Biostatistician, GSK

  • Study design and comparison with standard approach
  • The ‘issue’ with the interim analysis
  • Simulation plan and results
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    Latest developments in adaptive designs: a company's perspective - Sanofi-Aventis

    Loic Darchy

    Loic Darchy, Head of Statistical Sciences & Modeling France, Sanofi Aventis

  • Overview of the latest research at Sanofi
  • Examples of how Sanofi is currently using adaptive designs in their clinical trials 
  • Current issues being faced and challenges ahead
  • clock

    15:50

    A Case Study: Sequential trials in the context of competing risks

    Corine Baayen, Senior Biostatistician, Lundbeck Pharma

  • How can we evaluate competing risk data in group sequential trials?
  • A case study illustrating the state of the art, typical challenges and open issues
  • A discussion of remaining open questions
     
  • clock

    16:30

    Chairman’s Closing Remarks and Close of Day One

    Corine Baayen, Senior Biostatistician, Lundbeck Pharma

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca

    clock

    9:10

    Platform studies in drug development

    James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca

  • The use of Basket and Umbrella Studies
  • Benefits of a Platform Study approach in Oncology
  • Practical challenges with Platform Studies
  • Applications in other therapeutic areas
  • clock

    9:50

    Regulatory perspectives for the planning and assessment of umbrella and basket trials

    Olivier Collignon, Biostatistician, European Medicines Agency (EMA)

  • Evaluation of the consistency of response across several sub-studies based on different conditions, pooling of the sub-studies and impact on regulatory assessment
  • The debatable necessity to control for multiplicity
  • Additional issues relating to biomarker development and integration of historical controls
     
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Design and analysis of platform trials assessing multiple treatments and biomarkers

    James Wason, Group Leader, MRC Biostatistics Unit

  • How traditional trial design could be improved when treatments are expected to have different efficacy in different groups
  • A review and comparison of designs available for testing multiple treatments in multiple subgroups
  • An overview of methodology work done to address statistical issues arising when new treatments and biomarkers can be added in, including error rates, use of non-concurrent controls, planning confirmatory studies
  • A description of future research directions in this area
  • clock

    11:40

    Panel Discussion: experimental and novel approaches in adaptive designs

  • What experimental and novel approaches are being used by pharmaceutical companies?
  • Why are novel approaches used and what benefits do they bring?
  • Challenges associated with the use of novel adaptions
  • Future outlook for new experimental adaptions and novel approaches
  • Olivier Collignon, Biostatistician, European Medicines Agency (EMA)

    James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca

    Ros Walley, Statistician, UCB Pharma

    clock

    12:20

    Networking Lunch

    clock

    13:20

    Self adapting priors

    Ros Walley, Statistician, UCB Pharma

  • Incorporating relevant historical information though a Bayesian informative prior is increasingly used in Early Clinical Development
  • Concern about potential prior-data conflict can lead to heavy discounting of this information
  • Instead “self-adapting priors” can be used which alter the down-weighting depending on the discrepancy between the prior and the data
     
  • clock

    14:00

    The Role of Re-randomization Tests in Adaptive Methods with Planned or Unplanned Changes

    Michael Proschan, Mathmatical Statistician, National Institute of Allergy and Infectious Diseases

  • Unplanned changes can still be analysed in a valid way
  • The real null hypothesis being tested with covariate- and response-adaptive randomization
  • Temporal trends?  Re-randomization tests to the rescue!
  • Are re-randomization tests always valid?
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    Right Patient, Right Design : Facilitating Personalised HealthCare with Adaptive Designs

    Chris Harbron, Principal Statistical Scientist , Roche Products Ltd

  • Personalised HealthCare (PHC),  targeting therapies to those patients most likely to benefit is becoming increasingly important
  • During development there can be uncertainty on the optimal PHC strategy, both on the need for a biomarker and the exact definition of a biomarker
  • Adaptive designs provide an efficient way of mitigating this uncertainty whilst still maintaining the overall rigour and operating characteristics of the trial
     
  • clock

    15:50

    Adequate decision making in development programmes for targeted therapies

    Heiko Goette, Biostatistician, Merck & KGaA

  • Development programmes for targeted therapies usually consist of early phase trial for identifying a target subgroup among several biomarker candidates followed by a confirmatory trial
  • Design options for confirmatory trial: targeted subgroup enrichment design or adaptive enrichment design
  • Results from early phase trial influence go/no go decision, choice of confirmatory trial design as well as interim decision rule of adaptive design
  • Early phase results need to be adjusted for data-driven selection to allow adequate decision making
     
  • clock

    16:30

    Chairman’s Closing Remarks and Close of Day Two

    James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca


    Medical Assessor
    MHRA
    Managing Director
    Highbury Regulatory Science
    Principal Statistical Scientist
    Roche Products Ltd
    Professor of Statistics
    University Of Bath
    Executive Director Biostatistics
    Amgen
    Senior Biostatistician
    Lundbeck Pharma
    Biostatistician
    GSK
    Expert Statistician Methodology
    Boehringer-Ingelheim
    Biostatistician
    Merck & KGaA
    Head of Biometrics, Early Clinical Development
    AstraZeneca
    Group Leader
    MRC Biostatistics Unit
    Head of Statistical Sciences & Modeling France
    Sanofi Aventis
    Mathmatical Statistician
    National Institute of Allergy and Infectious Diseases
    Biostatistician
    European Medicines Agency (EMA)
    Statistician
    UCB Pharma
    Professor of Medical Statistics
    University of Reading
    Director of Software Solutions
    Berry Consultants, LLP

    Sponsors and Exhibitors

    Supporters

    PAST ATTENDEE LIST

    Download

    Speaker Interview - Daniela Casula, Lead Statistician, GlaxoSmithKline

    Download

    SPEAKER INTERVIEW - Tom Parke, Director of Software Solutions, Berry Consulting

    Download

    SPEAKER INTERVIEW - Frank Fleischer, Expert Statistician Methodology, Boehringer-Ingelheim

    Download

    SPEAKER INTERVIEW - Alex Novartis, Director & Statistical Scientist, Novartis

    Download

    Sponsors and Exhibitors


    GCE Solutions

    Sponsors and Exhibitors
    http://www.gcesolutions.com

    GCE Solutions is a global clinical research services and solutions organization specializing in all aspects of clinical data. GCE provides high caliber statistical support with unmatched biostatistics expertise. GCE’s experienced statisticians cover a wide range of therapeutic areas, all phases of clinical trials, submissions/publications, real world evidence, and data visualization. The company’s industry-recognized experts are globally located across the USA, Canada, Europe, India, Mexico, and South Africa. GCE’s key services are Statistical Programming, Biostatistics, Data Management, Data Provisioning, Data Visualization, Medical Writing, RBM, Biometrics Software, and Clinical IT.


    Mevia

    Sponsors and Exhibitors
    http://www.mevia.se

    Mevia helps patients adhere to their medication. Our technology allows for real-time monitoring and support to allow for better data quality and faster clinical trials. With our suite of medication support solutions we are able to not only measure directly in the package when a pill is taken but also support through sms, email, automated phone calls or push notifications through our app.

    Media Partners


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    evvnt Ltd

    Supporters
    http://www.evvnt.com

    evvnt enables people all over the world to fill their events utilising the most effective event listing sites on the web. Every minute, with little more than a click, more events and conferences appear in listings, in search engines and on mobile - discoverable by both category and location. With next to no effort customers of evvnt get better attendance, while consumers find events they previously had no idea existed. To date customers in 70 countries worldwide have submitted over 500,000 thousand event listings, created over 300,000 live links, and generated 1 million clicks to ticketing and registration pages. Learn more at www.evvnt.com


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.